Clinical trials: Glucocorticoid-induced Glucometabolic Abnormalities
Glucocorticoid-induced Glucometabolic Abnormalities, Glucocorticoid-induced Beta-cell Dysfunction
PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide
The purpose of this study is to explore whether the GLP-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.
- Trial name
- PREDEX (NCT00744224)
- Testing
- Prednisolone, Prednisolone and Exenatide
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc